Olympus, Boston Scientific & more — 3 GI company key notes

Here are three updates on gastroenterology and endoscopy companies.

Advertisement

Paris, France-based Nanobiotix reported the results of its phase I/II clinical trial for NBTXR3, its liver cancer drug.

Three senior Olympus executives utilized their right to invoke the Fifth Amendment during questioning over internal company emails.

Following news about superbug outbreaks at numerous facilities, providers and hospitals are trying out disposable scopes, such as Boston Scientific’s single-use bronchoscope.

More articles on gastroenterology and endoscopy:
Which lifestyle factors are associated with serrated colorectal polyps? 5 study insights
AGA critiques ABIM maintenance of certification announcement: 3 takeaways
Biggest hepatology breakthroughs in 2016: Nonalcoholic steatohepatitis, primary biliary cholangitis

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • Gastroenterology continues to evolve rapidly as advances in colorectal cancer prevention, inflammatory bowel disease research, microbiome science and outpatient digestive…

Advertisement

Comments are closed.